Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 421 participants across four groups. All participants had Alzheimer's disease and were being studied in relation to a drug called lanabecestat at two different doses (20 mg and 50 mg). The trial was structured so that some participants started on a placebo (an inactive treatment) before switching to lanabecestat, while others received lanabecestat from the beginning. The study measured changes in cognition (thinking and memory), daily activities, and overall functioning using several standardised rating scales. Notably, the vast majority of participants did not complete the trial — only one person out of 421 was recorded as having completed it — which is important context for understanding all of the numbers below. The reported data shows the following changes from the start of the trial to its end across the four groups. On the primary measure — a cognitive test called the ADAS-Cog13 (scored 0–85, where higher numbers mean worse cognition) — scores increased (worsened) by between approximately 8.4 and 10.4 points across all groups. On a daily activities scale (ADCS-iADL, scored 0–59, where lower numbers mean worse ability), scores fell by between roughly 7.4 and 9.2 points across groups. On a separate daily activities questionnaire (FAQ, scored 0–30, where higher means greater difficulty), scores rose by between about 6.3 and 7.1 points across groups. On a combined cognition-and-function scale (iADRS, scored 0–144, where higher means greater impairment), scores worsened by between approximately 15.4 and 18.9 points. On a general cognitive test (MMSE, scored 0–30, where lower means worse), scores fell by between roughly 4.7 and 5.8 points across groups. A second reported ADAS-Cog13 analysis showed score increases of between approximately 12.4 and 16.8 points across groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Alzheimer's Disease Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must have already taken part in a previous clinical trial called AMARANTH (NCT02245737) and still meet the requirements to continue into this new phase of the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- If you were part of the AMARANTH trial (NCT02245737) but have since developed any new health conditions that would prevent you from safely joining this follow-on study, you would not be eligible (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 7 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Change From Baseline Analysis on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)
Other options
Data last synced from ClinicalTrials.gov: 14 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.